RESUMO
BACKGROUND: Depressive disorder after myocardial infarction (MI) is associated with increased cardiac morbidity and mortality. Immune activity such as inflammation might be implicated as an underlying mechanism. The purpose of this study is to investigate whether the response to an antidepressant in post-MI depression is associated with changes of inflammatory markers in serum. METHODS: In a double-blind placebo-controlled study with mirtazapine 30 mg/day (50 patients), the antidepressive effect was related to immune activation parameters. The cytokines interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), the soluble cytokine receptors sIL-6R, sTNF-R1 and sTNF-R2, and the inflammation-sensitive plasma proteins C-reactive protein and neopterin were assessed. RESULTS: Subgroup analyses revealed a highly significant correlation of pronounced sTNF-R1 increase with a decrease in depressive symptoms in antidepressant responders. CONCLUSION: Significant effects on inflammation accompany the therapeutic efficacy of mirtazapine in contrast to the therapeutic efficacy of placebo and the nontherapeutic efficacy of mirtazapine.
Assuntos
Antidepressivos Tricíclicos/uso terapêutico , Depressão/tratamento farmacológico , Depressão/imunologia , Mianserina/análogos & derivados , Infarto do Miocárdio/complicações , Infarto do Miocárdio/imunologia , Receptores Tipo I de Fatores de Necrose Tumoral/efeitos dos fármacos , Adulto , Idoso , Antidepressivos Tricíclicos/farmacologia , Depressão/sangue , Depressão/complicações , Feminino , Humanos , Mediadores da Inflamação/sangue , Masculino , Mianserina/farmacologia , Mianserina/uso terapêutico , Pessoa de Meia-Idade , Mirtazapina , Infarto do Miocárdio/sangue , Infarto do Miocárdio/tratamento farmacológico , Receptores Tipo I de Fatores de Necrose Tumoral/sangueRESUMO
BACKGROUND: The decrease of maternal docosahexaenoic (DHA) status during pregnancy has been associated with postpartum depression, especially in women with a low intake of DHA. Since the DHA intake in the Netherlands is low, we investigated whether supplementation of low doses of DHA or DHA plus arachidonic acid (AA) during pregnancy and lactation could prevent depressive symptoms and sleep disturbances in this period. METHODS: Women were supplemented daily with placebo, DHA (220 mg) or DHA+AA (220 mg each) from week 16 of pregnancy till three months postpartum. Fatty acid analyses were performed in the available plasma samples at 16 and 36 weeks of pregnancy. Depressive symptoms were measured in weeks 16 and 36 of pregnancy and six weeks postpartum using EPDS and within one week postpartum using a blues questionnaire. RESULTS: 119 women completed the study. The average frequency of fish intake was low, 0.94 times per week, and did not differ between the groups. The supplementation groups did not differ in mean EPDS scores or changes in EPDS scores, nor in incidence or severity of postpartum blues. Red blood cell DHA, AA and DHA/AA ratio did not correlate with EPDS or blues scores. Indices of sleep quality did not differ between the groups. CONCLUSION: Supplementation of 220 mg/day DHA or DHA+AA (220 mg/day each) does not prevent peri-partum depressive symptoms, in a population based sample with low background DHA intake. TRIAL REGISTRATION: ISRCTN Register nr. ISRCTN58176213.
Assuntos
Ácido Araquidônico/administração & dosagem , Depressão Pós-Parto/prevenção & controle , Suplementos Nutricionais , Ácidos Docosa-Hexaenoicos/administração & dosagem , Adulto , Ácido Araquidônico/sangue , Ácidos Docosa-Hexaenoicos/sangue , Feminino , Humanos , Placebos , Gravidez , Sono/efeitos dos fármacosRESUMO
OBJECTIVE: Assessment of the temporal interrelationship of neuropsychiatric parameters requires technologies allowing frequent biological measurements. We propose glucocorticoid receptor (GR) function of lymphocytes to assess the temporal relationship between glucocorticoid resistance and the course of major depressive disorder. METHOD: Dexamethasone suppression of lymphocyte proliferation was in vitro assessed via 5-bromo-2' deoxyuridine (BrdU) incorporation in DNA. Optimal conditions were determined using blood of healthy volunteers. Thereafter the relation between depression severity (Hamilton Depression Rating Scale, HDRS, scores), lymphocyte proliferation and morning cortisol levels in blood was studied in thirteen depressed patients, mostly with a history of treatment resistance. RESULTS: Recovery from depression was not directly associated with changes in lymphocyte glucocorticoid resistance. However, a negative correlation was observed between HDRS and BrdU incorporation and a positive correlation between morning cortisol and BrdU incorporation. No significant correlation was found between cortisol and HDRS. Regression analyses showed that HDRS was related to both suppression of BrdU incorporation (beta -0.508, p<0.001) and cortisol levels (beta 0.364, p=0.001) in a highly significant model (F2,60=14,244, p<0.001) Except for one case, such relation could not be found within patients. CONCLUSION: Our preliminary results suggest a mutual relation between lymphocyte GR function, morning cortisol levels and MDD symptom severity. A direct relation between glucocorticoids resistance and recovery may not exist, but glucocorticoid resistance might attenuate or prevent recovery. It is clear that additional studies using larger and more homogenous groups of MDD patients are required to support our findings.
Assuntos
Depressão/patologia , Linfócitos/fisiologia , Receptores de Glucocorticoides/fisiologia , Bromodesoxiuridina/metabolismo , Contagem de Células , Proliferação de Células/efeitos dos fármacos , Dexametasona/farmacologia , Relação Dose-Resposta a Droga , Feminino , Glucocorticoides/farmacologia , Humanos , Ativação Linfocitária , Linfócitos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Análise de RegressãoRESUMO
The development of effective and safe drugs for a growing Alzheimer disease population is an increasing need at present. Both experimental and clinical evidence support a beneficial effect of proline-rich polypeptides in a number of neurodegenerative diseases, including Alzheimer disease. Experimental data have shown that proline-rich polypeptides isolated from bovine neurohypophisis possess neuroprotective and neuromodulatory properties in mice with aluminum neurotoxicosis or neuronal damage caused by venoms and toxins. Proline-rich polypeptides from ovine colostrums, so called Colostrinin, have been shown to produce cognitive improvement in an experimental model and in patients with Alzheimer disease. However, the precise mechanism underlying the neuroprotective action of proline-rich polypeptides is not very well established. Moreover, studies pointing at a neuroprotective effect of proline-rich polypeptides from bovine neurohypophisis in humans have not been reported thus far. The authors conclude that more detailed information on the mode of action of proline-rich polypeptides is needed as well as confirmation of their efficacy in broad clinical trials before this approach can really show its potential in the treatment of neurodegenerative disorders.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Doenças Neurodegenerativas/tratamento farmacológico , Peptídeos/uso terapêutico , Prolina/uso terapêutico , Animais , Caspases/metabolismo , Ensaios Clínicos como Assunto , Cognição/efeitos dos fármacos , Síndrome de Esmagamento/tratamento farmacológico , Humanos , Hipotálamo/metabolismo , Imunidade/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Síndromes Neurotóxicas/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Peptídeos/química , Peptídeos/metabolismo , Hipófise/metabolismo , Prolina/químicaRESUMO
Affective disorders are common psychiatric illnesses characterized by marked gender-related prevalence. Recent evidence links chronic stress and dysregulation of neurotrophin signaling with the development of depression, while novel theories suggest that antidepressants may act by promoting intracellular adaptations linked to neuroplasticity. Although selective serotonin reuptake inhibitors (SSRIs) efficaciously improve a variety of dysfunctions in males, their neuroendocrine effects and intracellular signaling patterns in females are not well determined. Here we show that chronic footshock stress (21 days) promotes HPA axis hyperactivity (as seen by the increased FOS-ir in the paraventricular hypothalamic nucleus (PVN), plasma corticosterone and adrenal hypertrophy), reduces hippocampal BrdU immunoreactivity and suppresses cortical-limbic CREB phosphorylation in female rats. Long-term citalopram treatment, in contrast, attenuates stress-induced elevation of corticosterone levels and adrenal hypertrophy, although it does not reverse footshock-mediated induction of FOS-ir in the PVN, inhibition of CREB phosphorylation and reduction of hippocampal BrdU-labeling. Moreover, citalopram administration was also associated with significant hypophagic effects and inhibition of CREB phosphorylation. These data suggest that, in female rats, normalization of chronic stress-induced HPA axis abnormalities may represent an initial phase of citalopram-mediated therapeutic actions and despite this SSRI's apparent lack of effects on neuroplasticity, we cannot exclude the possibility that some neurochemical adaptations occur in a later stage which may require more than 3 weeks of treatment to manifest.
Assuntos
Proteína de Ligação a CREB/metabolismo , Citalopram/uso terapêutico , Proteínas Proto-Oncogênicas c-fos/metabolismo , Estresse Psicológico/tratamento farmacológico , Estresse Psicológico/fisiopatologia , Animais , Antidepressivos de Segunda Geração/uso terapêutico , Bromodesoxiuridina , Proteína de Ligação a CREB/efeitos dos fármacos , Corticosterona/sangue , Eletrochoque , Imuno-Histoquímica , Masculino , Proteínas Proto-Oncogênicas c-fos/efeitos dos fármacos , Ratos , Ratos Wistar , Aumento de Peso/efeitos dos fármacosRESUMO
We assessed essential fatty acid (EFA) and B-vitamin status, together with their determinants, in 61 patients with schizophrenia and established whether those with poor status responded biochemically to the appropriate dietary supplements. As a group, the patients had high erythrocyte saturated fatty acids (FAs), monounsaturated FA and low polyunsaturated FA of the omega3 and omega6 series. Patients reporting not to take vitamin supplements had low vitamin B12 and high homocysteine. Homocysteine variance proved best explained by folate in both the total group and male patients, and by vitamins B12 and B6 in females. Alcohol consumption and duration of illness are risk factors for low polyunsaturated FA status (< P2.5 of reference range), while male gender and absence of fish consumption predict hyperhomocysteinemia (> P97.5 of reference range). Two patients exhibited biochemical EFA deficiency and seven showed biochemical signs of omega3/docosahexaenoic acid (DHA) marginality. Four patients exhibited moderate hyperhomocysteinemia with plasma values ranging from 57.5 to 74.8 micromol/L. None of the five patients with either moderate hyperhomocysteinemia, biochemical EFA deficiency, or both, was predicted by their clinicians to have poor diets. That diet was nevertheless at the basis of these abnormalities became confirmed after supplementing 4 of them with B vitamins and with soybean and fish oils. We conclude that a subgroup of patients with schizophrenia has biochemical EFA deficiency, omega3/DHA marginality, moderate hyperhomocysteinemia, or combinations. Correction seems indicated in view of the possible relation of poor EFA and B-vitamin status with some of their psychiatric symptoms, but notably to reduce their high risk of cardiovascular disease.
Assuntos
Suplementos Nutricionais , Ácidos Graxos Essenciais/administração & dosagem , Esquizofrenia/dietoterapia , Vitamina B 12/sangue , Vitamina B 6/sangue , Complexo Vitamínico B/uso terapêutico , Deficiência de Vitaminas do Complexo B/dietoterapia , Adolescente , Adulto , Estudos Transversais , Eritrócitos/química , Eritrócitos/metabolismo , Ácidos Graxos/análise , Ácidos Graxos Essenciais/deficiência , Ácidos Graxos Essenciais/metabolismo , Feminino , Óleos de Peixe/administração & dosagem , Homocisteína/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Estado Nutricional , Fatores Sexuais , Óleo de Soja/administração & dosagem , Vitamina B 12/uso terapêutico , Vitamina B 6/uso terapêutico , Deficiência de Vitaminas do Complexo B/sangue , Deficiência de Vitaminas do Complexo B/diagnósticoRESUMO
In addition to its well-recognized function as a cerebral inhibitory transmitter, less well established is the role of GABA in peripheral nervous and endocrine systems. We summarize current evidence that GABA serves as a neurotransmitter or neuromodulator in the autonomic nervous system and as a hormone or trophic factor in non-neuronal peripheral tissue as well. GABA is widely distributed in endocrine tissues including the pituitary, pancreas, adrenal glands, uterus, ovaries, placenta and testis. Moreover, GABA is involved in the pathophysiology of endocrine disorders such as diabetes mellitus, diseases of adrenal glands and reproductive tracts. Current literature indicates that the peripheral GABA system in the autonomic nervous system, endocrine and immune systems is as yet nearly an unexplored target for diagnosis and drug treatment.
Assuntos
Doenças do Sistema Endócrino/fisiopatologia , Ácido gama-Aminobutírico/fisiologia , Glândulas Suprarrenais/fisiologia , Animais , Humanos , Receptores de GABA/fisiologia , Reprodução/fisiologiaRESUMO
We investigated whether the lack of therapeutic response to long-term and adequate neuroleptic treatment was due to a failure to achieve a blockade of cerebral dopamine receptors. Six chronic schizophrenic and medicated patients (DSM-III-R diagnosis, paranoid or disorganized type) were assessed with the Present State Examination and the Brief Psychiatric Rating Scale. According to the Chouinard Rating Scale there were little extrapyramidal symptoms, although no anticholinergic drugs were given. Plasma levels of the neuroleptics were determined and found in the therapeutic range or higher. Dopamine D2-receptor occupancy was determined with positron emission tomography using 11C-methylspiperone as ligand. There was a more than 95% blockade of the D2 receptors in the striatum. These results indicate that the lack of therapeutic response and extra-pyramidal side effects cannot be attributed to an incomplete blockade of cerebral D2 receptors and that the pathogenetic role of these receptors can be questioned in therapy-resistant schizophrenic patients.
Assuntos
Antipsicóticos/uso terapêutico , Encéfalo/efeitos dos fármacos , Receptores Dopaminérgicos/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Espiperona/análogos & derivados , Tomografia Computadorizada de Emissão , Adulto , Antipsicóticos/efeitos adversos , Antipsicóticos/farmacocinética , Encéfalo/diagnóstico por imagem , Discinesia Induzida por Medicamentos/diagnóstico por imagem , Feminino , Humanos , Masculino , Escalas de Graduação Psiquiátrica , Receptores de Dopamina D2 , Esquizofrenia/diagnóstico por imagem , Espiperona/farmacocinéticaRESUMO
Lactic acid was measured continuously in the dialysis perfusate emerging from the striatum of conscious, freely moving rats. The continuous measurement utilized a specific enzymatic/fluorometric detector that provided temporal information about the changes in the concentration of lactate in extracellular fluid (ECF). The level of lactate in extracellular fluid was found to be directly linked to local cellular metabolism. Inhibition of glycolysis with 2-deoxyglucose decreased the ECF level of lactate, whereas increased lactate production was observed after uncoupling mitochondrial electron transport with 2,4-dinitrophenol. A transient increase in the extracellular level of lactate was found after neuronal stimulation (e.g., electroconvulsive shock or local administration of kainic acid). The response to electroconvulsive shock could be attenuated by inhibiting the electrical activity of neurons with tetrodotoxin. Thus, this system is capable of providing novel information about transient changes in the extracellular concentration of lactic acid in real time, and these changes can be related to changes in metabolism and neuronal activity.
Assuntos
Encéfalo/metabolismo , Corpo Estriado/metabolismo , Diálise , Espaço Extracelular/metabolismo , Lactatos/metabolismo , 2,4-Dinitrofenol , Animais , Encéfalo/efeitos dos fármacos , Corpo Estriado/efeitos dos fármacos , Desoxiglucose/farmacologia , Dinitrofenóis/farmacologia , Transporte de Elétrons/efeitos dos fármacos , Eletrochoque , Glicólise/efeitos dos fármacos , Ácido Caínico/farmacologia , Ácido Láctico , Masculino , Ratos , Ratos Endogâmicos , Tetrodotoxina/farmacologiaRESUMO
Intracerebral dialysis has allowed the continuous, on-line measurement of lactate in the extracellular fluid (ECF) of conscious, freely moving rats. The rapid time response of the technique allows the direct determination of the time course of changes in lactate in ECF following externally imposed stimuli. The time course of lactate appearance in ECF was found to be considerably slower than that observed in tissue following electroconvulsive shock or during ischemia following cardiac arrest. The ECF data could be fit to an integrated Michaelis-Menten model that assumed reversible transport of lactate across the cell membrane. This transport was found to act only when energy supplies could maintain membrane integrity and function, since ECF levels of lactate failed to follow tissue levels after cardiac arrest when energy resources are depleted. The calculated rate of cellular lactate transport was two orders of magnitude faster than transport of lactate across the blood-brain barrier in the adult rat, and passive diffusion of lactate was not found to contribute significantly across either cell or blood-brain barriers. Probenecid, an inhibitor of acid transport, was able to block both the efflux of lactate from cell to ECF and the consequent reuptake of lactate by cells in the striatum of the rat following electroconvulsive shock or ischemia.
Assuntos
Corpo Estriado/metabolismo , Lactatos/metabolismo , Animais , Transporte Biológico Ativo , Barreira Hematoencefálica , Permeabilidade da Membrana Celular , Espaço Extracelular/efeitos dos fármacos , Espaço Extracelular/metabolismo , Masculino , Probenecid/farmacologia , Ratos , Ratos EndogâmicosRESUMO
Hypoxia-ischemia is accompanied by abundant corticosterone secretion that could exacerbate brain damage after the insult. The authors demonstrate that the steroid synthesis inhibitor metyrapone (150 mg/kg subcutaneously) suppresses the hypoxia-ischemia-induced rise of plasma corticosterone levels (17.3 +/- 3.6 micrograms/dL) when compared with corticosterone-treated animals (72.2 +/- 4.8 micrograms/dL) immediately after hypoxia-ischemia. In parallel, metyrapone reduced brain damage (P < 0.05). Moreover, none of the metyrapone-treated animals displayed seizures, whereas seven of eight corticosterone-treated animals had seizures after hypoxia-ischemia. Although corticosterone administration in metyrapone-treated animals elevated plasma corticosterone levels (39.0 +/- 5.3 micrograms/dL), this did not result in a subsequent increase in brain damage and seizures when compared with metyrapone-treated animals. The authors conclude that metyrapone reduces brain damage and the incidence of seizures after hypoxia-ischemia but that this effect might partially be independent from its effect on modulating plasma corticosterone levels.
Assuntos
Dano Encefálico Crônico/prevenção & controle , Isquemia Encefálica/tratamento farmacológico , Corticosterona/sangue , Epilepsia/prevenção & controle , Hipóxia Encefálica/tratamento farmacológico , Metirapona/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Animais , Glicemia/análise , Temperatura Corporal , Dano Encefálico Crônico/etiologia , Isquemia Encefálica/complicações , Isquemia Encefálica/patologia , Epilepsia/etiologia , Hipóxia Encefálica/complicações , Hipóxia Encefálica/patologia , Locomoção , Masculino , Metirapona/farmacologia , Fármacos Neuroprotetores/farmacologia , Ratos , Ratos WistarRESUMO
Elimination of corticosteroids after ischemia, by removal of the adrenals, has been reported to preserve neuronal integrity later. To establish the therapeutic potential of this observation, the authors address two questions: first, whether clinically more relevant steroid manipulations after ischemia exert similar protective effects, and second, whether changes in synaptic functioning occur along with structural alterations. To test this, the authors treated animals immediately after hypoxia-ischemia with (1) the steroid synthesis inhibitor metyrapone, (2) the synthetic glucocorticoid receptor agonist dexamethasone, (3) the selective glucocorticoid antagonist RU 38486, or (4) corticosterone. Metyrapone, but none of the other compounds, attenuated the occurrence of seizures immediately after ischemia. Twenty-four hours after hypoxia-ischemia, CAI hippocampal field potentials in response to stimulation of Schaffer/commissural fibers were found to be reduced. The attenuation of synaptic transmission was partly prevented by metyrapone. None of the other experimental treatments influenced the impaired synaptic function. Gross morphologic analysis revealed no differences in the loss of neuronal structure between the experimental groups at this time point. Taken together, these data suggest that metyrapone preserves neuronal functioning despite loss of neuronal structure. The authors tentatively conclude that preventing the ongoing production of steroids shortly after ischemia can delay and attenuate the appearance of ischemia-related pathology.
Assuntos
Isquemia Encefálica/fisiopatologia , Hipocampo/irrigação sanguínea , Hipóxia Encefálica/fisiopatologia , Plasticidade Neuronal/fisiologia , Potenciais de Ação/fisiologia , Animais , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/patologia , Corticosterona/sangue , Dexametasona/farmacologia , Eletrofisiologia , Epilepsia/fisiopatologia , Potenciais Pós-Sinápticos Excitadores/fisiologia , Glucocorticoides/farmacologia , Hipocampo/química , Hipocampo/patologia , Antagonistas de Hormônios/farmacologia , Hipóxia Encefálica/tratamento farmacológico , Hipóxia Encefálica/patologia , Masculino , Metirapona/farmacologia , Proteínas Associadas aos Microtúbulos/análise , Mifepristona/farmacologia , Técnicas de Cultura de Órgãos , Células Piramidais/química , Células Piramidais/citologia , Células Piramidais/fisiologia , Ratos , Ratos WistarRESUMO
Equilibrium models are derived and applied to in vivo binding of spiperone in the rat brain. The models express the concentration of the ligand in the striatum and frontal cortex as a function of the accumulation in the cerebellum. The models differ with respect to the description of specific binding. Nonlinear regression analysis shows that the in vivo specific binding of 3H-labeled spiperone in the frontal cortex (mainly serotonergic) can be described by a noninteracting sites model, whereas the specific binding in the striatum (mainly dopaminergic) can best be described by models that lead to sigmoid saturation curves. These results were tested and partly confirmed by determining the region-of-interest/cerebellar radioactivity ratio of 11C-labeled N-methylspiperone, with and without pretreatment with haloperidol. The estimated Bmax was 32 fmol/mg wet tissue in the frontal cortex and approximately 90 fmol/mg wet tissue in the striatum. The free plus nonspecific binding of spiperone was similar in the frontal cortex but lower in the striatum than in the cerebellum. The occurrence of sigmoidicity can be best explained by the existence of high-affinity/low-capacity sites in the cerebellum rather than mutual interactions of striatal sites. The consequence of the present analysis for positron emission tomography is that the striatal/cerebellar activity ratio is not an accurate parameter of specific binding features at tracer doses of spiperone or N-methylspiperone.
Assuntos
Encéfalo/metabolismo , Dopaminérgicos/metabolismo , Receptores Dopaminérgicos/metabolismo , Receptores de Serotonina/metabolismo , Espiperona/análogos & derivados , Espiperona/metabolismo , Animais , Encéfalo/diagnóstico por imagem , Radioisótopos de Carbono , Cerebelo/metabolismo , Corpo Estriado/metabolismo , Lobo Frontal/metabolismo , Modelos Teóricos , Ratos , Tomografia Computadorizada de Emissão , TrítioRESUMO
Amino acid transmitters and cations were assessed in the frontal cortex and hippocampus of 12 Alzheimer's disease (AD), 4 multi-infarct dementia (MID) patients, and 12 age-matched controls. In the hippocampus, but not in the frontal cortex of AD patients we observed an increase of sodium (Na) and a decrease of potassium (K) and magnesium (Mg) content as compared to controls. Calcium (Ca) was not changed. These cation shifts were highly correlated with glutamate, which was significantly decreased in AD hippocampus. Hippocampal Na and K levels correlated also highly with gamma-aminobutyrate, cholineacetyltransferase and noradrenaline levels in the hippocampus and dementia scores. These results show that Na and K changes are sensitive markers for neurodegenerative processes in AD and suggest a loss of glutamatergic neurons in AD hippocampus.
Assuntos
Doença de Alzheimer/metabolismo , Demência/metabolismo , Lobo Frontal/metabolismo , Hipocampo/metabolismo , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/patologia , Aminoácidos/metabolismo , Cátions/metabolismo , Demência/patologia , Feminino , Lobo Frontal/patologia , Hipocampo/patologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
We determined whether food restriction or the drugs nimodipine (Ca2+ antagonist) and deprenyl (a MAO-B inhibitor) prevent the development of stroke in the spontaneously hypertensive stroke-prone rat (SHR-SP). Forty male SHR-SP rats, in the age of 34 weeks, were exposed to various treatments. During a period of 27 weeks, survival and blood pressure were followed. In the control and deprenyl group, the blood pressure values remained unchanged; 50% had died after 27 weeks. All rats that were treated with nimodipine survived. After food restriction, 7/8 rats survived and showed a lower blood pressure. This study in SHR-PR rats shows the superiority of nimodipine on survival, and the potential of food restriction as a stroke-preventing measure.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Bloqueadores dos Canais de Cálcio/farmacologia , Transtornos Cerebrovasculares/fisiopatologia , Privação de Alimentos/fisiologia , Longevidade/efeitos dos fármacos , Inibidores da Monoaminoxidase/farmacologia , Nimodipina/farmacologia , Selegilina/farmacologia , Animais , Peso Corporal/efeitos dos fármacos , Transtornos Cerebrovasculares/genética , Expectativa de Vida , Masculino , Ratos , Ratos Endogâmicos SHR , Análise de SobrevidaRESUMO
The authors studied the relation between human central dopamine (DA) metabolism and the clinical effects of neuroleptics. The neuroleptic-induced increase in central DA turnover (an indicator for the degree of DA receptor blocking) was found to be positively correlated with the therapeutic effect of neuroleptics and the development of hypokinetic-rigid symptoms. This supplies a direct argument in support of the contention that DA antagonism is related to the occurrence of clinical effects. The authors also found indications that neuroleptics of different chemical types do not significantly differ in their intrinsic ability to provoke hypokinetic-rigid symptoms, that development of these symptoms depends on the patient's individual susceptibility, and that individual susceptibility is based on relatively low DA turnover.
Assuntos
Doenças dos Gânglios da Base/induzido quimicamente , Dopamina/metabolismo , Transtornos Mentais/tratamento farmacológico , Tranquilizantes/uso terapêutico , Adulto , Idoso , Antiparkinsonianos/uso terapêutico , Doenças dos Gânglios da Base/tratamento farmacológico , Clorpromazina/uso terapêutico , Antagonistas de Dopamina , Relação Dose-Resposta a Droga , Feminino , Haloperidol/uso terapêutico , Ácido Homovanílico/líquido cefalorraquidiano , Humanos , Ácido Hidroxi-Indolacético/líquido cefalorraquidiano , Individualidade , Masculino , Pessoa de Meia-Idade , Perfenazina/uso terapêutico , Placebos , Tranquilizantes/efeitos adversos , Tranquilizantes/farmacologiaRESUMO
The authors examined central catecholamine metabolism in various symptomatological psychotic disorders and the relationship between the biochemical and therapeutic action profiles of neuroleptics. Haloperidol and (to a lesser entent) chlorpromaziner icrease the dopamine (DA) turnover in the central nervous system, but the authors influenced; oxypertine has the reverse effect. The authors question whether disorders of DA-metabolism underlie or result from disorders of motor activity, postulating that the hyperdopaminergic activity observable in psychoses is dependent on motor hyperactivity rather than on "true" or psychotic symptoms such as delusions and hallucinations.
Assuntos
Encéfalo/metabolismo , Catecolaminas/metabolismo , Transtornos Psicóticos/tratamento farmacológico , Tranquilizantes/uso terapêutico , Adolescente , Adulto , Química Encefálica/efeitos dos fármacos , Clorpromazina/farmacologia , Depressão Química , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Feminino , Haloperidol/farmacologia , Humanos , Masculino , Metoxi-Hidroxifenilglicol/líquido cefalorraquidiano , Pessoa de Meia-Idade , Transtornos dos Movimentos , Norepinefrina/metabolismo , Piperazinas/farmacologia , Transtornos Psicóticos/líquido cefalorraquidiano , Transtornos Psicóticos/metabolismo , Estimulação Química , Tranquilizantes/farmacologiaRESUMO
OBJECTIVE: Elevated D8/17 expression on B lymphocytes is a known susceptibility marker of rheumatic fever. Previous studies have reported higher than usual D8/17 expression on B lymphocytes of patients with tic disorders. The purpose of this study was to assess D8/17 expression on B lymphocytes of tic disorder patients by using an objective method in which no operator variability was involved. METHOD: D8/17 expression on B lymphocytes was assessed with flow cytometry by using an immunoglobulin M (IgM) monoclonal D8/17-specific antibody in an unselected group of Dutch patients with tic disorders (N=33) and healthy volunteers (N=20). Binding of this monoclonal antibody was compared with binding of an irrelevant IgM monoclonal antibody, and the shift in mean fluorescence intensity of the D8/17-specific antibody compared to that of the irrelevant IgM monoclonal antibody was used as a measure of D8/17 overexpression. For the patients, Yale Global Tic Severity Scale scores were used to assess disease severity. RESULTS: D8/17 overexpression in the patient group (mean=16.8 arbitrary units, SD=30.5) was significantly higher than in the comparison group (mean=3.2, SD=3.0). A significant minority of the patients (N=13, 39.4%), however, had levels of D8/17 overexpression within the range of that of the healthy comparison subjects. Flow cytometric analysis did not indicate a separate subpopulation of D8/17-positive B cells. CONCLUSIONS: These data confirm the utility of D8/17 B cell overexpression as a peripheral blood marker in patients with tic disorders and are compatible with a streptococcus-related pathogenesis for at least a subgroup of patients with tic disorders.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos/imunologia , Linfócitos B/imunologia , Transtornos de Tique/imunologia , Adolescente , Adulto , Anticorpos Monoclonais/metabolismo , Antígenos/análise , Autoimunidade/imunologia , Linfócitos B/metabolismo , Biomarcadores , Criança , Feminino , Citometria de Fluxo , Humanos , Imunoglobulina M/imunologia , Masculino , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Febre Reumática/imunologia , Índice de Gravidade de Doença , Infecções Estreptocócicas/imunologia , Streptococcus/imunologia , Transtornos de Tique/diagnósticoRESUMO
Free radical species arise from the univalent reduction of oxygen. The cytosolic agent H2O2, produced during enzymatic scavenging of the superoxide radical (O2-) is in turn removed predominantly via the oxidation of reduced glutathione (GSH) to the oxidized form (GSSG) by glutathione peroxidase. Subsequently GSSG is recycled back to GSH by glutathione reductase (GSH-red). Little is known about the distribution of this enzyme in the brain. The aim of this study was to determine the distribution of this enzyme in the brain of different murine species by means of immunocytochemical techniques, although most attention was given to the distribution of GSH-red in the forebrain. In most brain areas GSH-red positive neurons were detected, but the regional intracellular staining intensity differed markedly. The pre-piriform and piriform cortices, the pyramidal cell layers of the hippocampus, and the dentate gyrus were heavily stained. The caudate nucleus displayed a progressive increase in the intracellular staining intensity from the rostral to the caudolateral parts. Furthermore, in the thalamus, there was a gradual decrease in GSH-red staining from the medial to the lateral parts. The mesencephalon was poor in immunopositive cells, and in the substantia nigra pars reticulata, almost no labeling was detected. However, the substantia nigra pars compacta showed an intense GSH-red immunoreactivity. The results show a specific localization of glutathione reductase in distinct brain regions, suggesting a variable potency of different brain areas in dealing with the damaging oxidative actions of free radicals. Also, differential GSH-red expression patterns were found in the various murine species. Some species showed a pronounced GSH-red immunoreactivity in glial cells, specifically in regions that lacked neuronal GSH-red immunoreactivity.
Assuntos
Astrócitos/química , Mapeamento Encefálico/métodos , Encéfalo/enzimologia , Proteína Glial Fibrilar Ácida/análise , Glutationa Redutase/análise , Animais , Especificidade de Anticorpos , Biomarcadores/química , Encéfalo/citologia , Radicais Livres , Técnicas Imunoenzimáticas , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Prosencéfalo/química , Ratos , Ratos Wistar , Rombencéfalo/química , Coloração e RotulagemRESUMO
The cations, calcium, magnesium, sodium, and potassium, putative amino acid transmitters, and total protein contents were assessed in the frontal cortex, putamen, and substantia nigra of Huntington's disease (HD) patients and age-matched nonneurologic control subjects. In the HD frontal cortex and HD substantia nigra, only small increases in sodium levels and decreases in potassium levels were observed, but in the HD putamen there were major cation shifts, suggesting a twofold increase of the extracellular space. In all three brain areas that were investigated, potassium was positively correlated with gamma-aminobutyric acid and in the putamen sodium was negatively correlated with the amino acid. These correlations suggest loss of gamma-aminobutyric acidergic neurons or nerve terminals in these areas. The elevation of sodium in the HD basal ganglia may be visualized in vivo by nuclear magnetic resonance of sodium.